--GRK-1172 Alumni Network -- Stay connected - be part of our story--

Welcome at GRK1172 -

Trendsetting biotechnologically produced drug classes as topic of the dissertation.

 

For more than 100 years, drug research, development and security (R&D) have been a major focus of academic and non-academic research in the Frankfurt area. In recent years, therapeutic biomolecules (biologicals or biopharmaceutical drugs) have proven to have a great innovative potential and the number of newly approved biologicals has increased dramatically. However, these biologicals are almost exclusively protein drugs that act extracellularly, such as antibodies, cytokines and growth factors. Other biotechnologically fabricated substance classes are rarely found in drug pipelines of the pharmaceutical industry.

In the research training group (GRK1172) especially innovative research on biologicals in Frankfurt, such as the development of therapeutic RNAs, intracellularly active proteins and gene therapy, is brought together. All stages of drug R&D, from target validation to Phase I and II clinical trials, are represented. The GRK is open for graduate students from the Natural Sciences, Medicine, Pharmacy, and Biotechnology. The supervising scientists are either affiliated with the faculties of Medicine and of Chemical and Pharmaceutical Sciences or they work at the Biomedical Research Institute Georg-Speyer-Haus and at the Paul-Ehrlich-Institut. Thus, knowledge and know-how from a broad range of diverse fields (Chemistry, Biochemistry, Cell Biology, Molecular Biology, Pharmacy, Pharmacology und Toxicology, Clinical Pharmacology, Clinical Medicine, Biotechnology, drug approval) are represented by the super-visors within the GRK and are fully accessible to the students. This interdisciplinary environment is an essential prerequisite for a successful PhD thesis on drug development and can rarely be provided within one research group alone. Unique in Germany, an extensive education to the topic of the dissertation and moreover to the process of development of new biopharmaceutical drugs is offered which exceeds the possibilities of a single supervisor.

The primary aim of the GRK is to educate the graduate students so that they can develop into independent and creative researchers. This is the primary task of the supervisor and the two co-supervisors. Furthermore, the students will learn to present and discuss their work in the internal seminars and workshops. In addition, the basic knowledge and technological know-how required for the development of new drugs is taught. For all stages of drug development and all types of therapeutic biomolecules, projects within the GRK are used to exemplify the teachings. Thereby, teaching and research within the GRK become synergistic. This broad education serves as a sound basis for a career in academic or non-academic drug R&D.

Coordinator: Prof. Dr. Josef Pfeilschifter
Fachbereich Medizin, pharmazentrum frankfurt
Institut für Allgemeine Pharmakologie und Toxikologie
Klinikum der Goethe-Universität
60590 Frankfurt am Main

Stellvertretenden Sprecher: Prof. Dr. Heinfried H. Radeke

Fachbereich Medizin, pharmazentrum frankfurt
Institut für Allgemeine Pharmakologie und Toxikologie
Klinikum der Goethe-Universität
60590 Frankfurt am Main

Administration: Silvia Koob
Georg-Speyer-Haus
Paul-Ehrlich-Straße 42-44
60596 Frankfurt am Main
Tel.: +49 (0) 69 / 63395-255
Fax: +49 (0) 69 / 63395-145